Lumenis Introduces FoLix

Lumenis, a leading energy-based medical device company, has announced the launch of FoLix, a revolutionary non-ablative fractional laser system designed to combat hair loss using advanced hair stimulation technology.

Recently cleared by the Food and Drug Administration (FDA), FoLix is now the first and only fractional laser option in the United States that offers a safe, effective, and natural treatment for hair loss in both women and men.

Hair loss is a prevalent issue that impacts over 85% of men and 50% of women. FoLix aims to address this with an innovative approach that utilises fractional laser and Lumenis’ proprietary technology tailored for hair. This new treatment promises significant results within 4-6 monthly sessions, all without the need for chemicals, needles, anaesthesia, surgery, or downtime.

The technology behind FoLix delivers precise laser pulses that stimulate the body’s natural processes to rejuvenate hair follicles. According to Lumenis’ pre-clinical and clinical studies, this method has shown a positive impact on hair growth, with noticeable improvements in scalp hair appearance and an increase in hair count.

“Fractional lasers have been shown to have remarkable effects on the skin and now, finally, Lumenis has been able to harness that power and bring an innovative solution for hair stimulation,” said Dr. Marc Avram, a renowned hair transplant specialist and Clinical Professor of Dermatology at Weill Cornell Medical College (WCMC).

Dr. Neil Sadick, a leading dermatologist and researcher, and Clinical Professor of Dermatology at WCMC, added, “With hair loss becoming a growing concern, FoLix emerges as a pivotal innovation for both patients and providers. FoLix offers a unique opportunity to help those suffering from hair loss through short monthly sessions and with minimal discomfort and no downtime.”

Lumenis is a pioneer in the field of laser aesthetics and a worldwide leader in energy-based aesthetic devices, including Intense Pulsed Light (IPL) and Radiofrequency (RF). For over 50 years, Lumenis’ innovations have redefined medical treatments, set technological and clinical gold standards, revolutionised existing treatment methods, and created solutions for previously untreatable conditions.

To find out more about FoLix, visit lumenis.com.